Auron Therapeutics

Abcuro Inc.’s venture capital investors showed confidence in the ongoing Phase II/III MUSCLE clinical trial of ulviprubart (ABC008) in inclusion body myositis (IBM) by putting their support behind a $

Pharma executives no longer ask whether AI is important in their industry – that much is certain, and it is already ubiquitous. As Lamine Mbow , global head of discovery research at Boehringer Ingelh

Venture capital fundraising by biopharmaceutical firms in the second quarter was a mixed bag, according to Venture Monitor data from Pitchbook and the National Venture Capital Association (NVCA), wh

ARCH Venture Partners raised its largest venture capital fund yet, the $1.85bn ARCH Venture Fund XI, which it plans to invest in a range of biotechnology opportunities, including drug developers focus